Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Stock Information for PLUS THERAPEUTICS Inc.
Loading
Please wait while we load your information from QuoteMedia.